Patient-reported reasons for declining same-day antiretroviral therapy initiation in routine HIV care settings in Lusaka, Zambia: results from a mixed-effects regression analysis.


Journal

Journal of the International AIDS Society
ISSN: 1758-2652
Titre abrégé: J Int AIDS Soc
Pays: Switzerland
ID NLM: 101478566

Informations de publication

Date de publication:
07 2020
Historique:
received: 22 12 2019
revised: 14 05 2020
accepted: 04 06 2020
entrez: 4 7 2020
pubmed: 4 7 2020
medline: 13 5 2021
Statut: ppublish

Résumé

In the current "test and treat" era, HIV programmes are increasingly focusing resources on linkage to care and same-day antiretroviral therapy (ART) initiation to meet UNAIDS 95-95-95 targets. After observing sub-optimal treatment indicators in health facilities supported by the Centre for Infectious Disease Research in Zambia (CIDRZ), we piloted a "linkage assessment" tool in facility-based HIV testing settings to uncover barriers to same-day linkage to care and ART initiation among newly identified people living with HIV (PLHIV) and to guide HIV programme quality improvement efforts. The one-page, structured linkage assessment tool was developed to capture patient-reported barriers to same-day linkage and ART initiation using three empirically supported categories of barriers: social, personal and structural. The tool was implemented in three health facilities, two urban and one rural, in Lusaka, Zambia from 1 November 2017 to 31 January 2018, and administered to all newly identified PLHIV declining same-day linkage and ART. Individuals selected as many reasons as relevant. We used mixed-effects logistic regression modelling to evaluate predictors of citing specific barriers to same-day linkage and ART, and Fisher's Exact tests to assess differences in barrier citation by socio-demographics and HIV testing entry point. A total of 1278 people tested HIV positive, of whom 126 (9.9%) declined same-day linkage and ART, reporting a median of three barriers per respondent. Of these 126, 71.4% were female. Females declining same-day ART were younger, on average, (median 28.5 years, interquartile range (IQR): 21 to 37 years) than males (median 34.5 years, IQR: 26 to 44 years). The most commonly reported barrier category was structural, "clinics were too crowded" (n = 33), followed by a social reason, "friends and family will condemn me" (n = 30). The frequency of citing personal barriers differed significantly across HIV testing point (χ Given differences observed in barriers to same-day ART initiation reported across sex, age, testing point, and facility type, new, tailored counselling and linkage to care approaches are needed, which should be rigorously evaluated in routine programme settings.

Identifiants

pubmed: 32618137
doi: 10.1002/jia2.25560
pmc: PMC7333172
doi:

Substances chimiques

Anti-HIV Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e25560

Informations de copyright

© 2020 The Authors. Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of International AIDS Society.

Références

PLoS One. 2010 Mar 04;5(3):e9538
pubmed: 20209059
PLoS Med. 2018 Jan 12;15(1):e1002489
pubmed: 29329301
JAMA. 2019 Feb 5;321(5):451-452
pubmed: 30629090
Curr HIV/AIDS Rep. 2019 Aug;16(4):324-334
pubmed: 31230342
AIDS Behav. 2013 Jan;17(1):274-83
pubmed: 22610422
PLoS One. 2015 Aug 11;10(8):e0135621
pubmed: 26262840
AIDS Behav. 2019 Sep;23(Suppl 2):120-128
pubmed: 31161462
AIDS Behav. 2015 Apr;19(4):704-14
pubmed: 25304330
BMC Public Health. 2010 Oct 12;10:601
pubmed: 20939872
AIDS Behav. 2019 Apr;23(4):929-946
pubmed: 30415432
PLoS Med. 2017 May 2;14(5):e1002292
pubmed: 28464041
AIDS Behav. 2018 Nov;22(11):3751-3762
pubmed: 29556834
AIDS. 2016 Jun 19;30(10):1639-53
pubmed: 27058350
J Acquir Immune Defic Syndr. 2011 Nov 1;58(3):344-52
pubmed: 21836524
Health Educ Q. 1988 Winter;15(4):351-77
pubmed: 3068205
PLoS Med. 2016 Aug 09;13(8):e1002107
pubmed: 27504637
AIDS Behav. 2018 Mar;22(3):691-700
pubmed: 28752353
J Acquir Immune Defic Syndr. 2009 Jun 1;51(2):135-9
pubmed: 19504725
J Acquir Immune Defic Syndr. 2017 May 1;75 Suppl 1:S43-S50
pubmed: 28398996
AIDS Care. 2018 Dec;30(12):1477-1487
pubmed: 30037312
J Int AIDS Soc. 2016 Dec 01;19(1):21484
pubmed: 27914186
Soc Sci Med. 2009 Jun;68(12):2271-8
pubmed: 19394121
J Acquir Immune Defic Syndr. 2019 Aug 15;81(5):540-546
pubmed: 31021988
AIDS. 2012 Oct 23;26(16):2059-67
pubmed: 22781227
Trop Med Int Health. 2011 May;16(5):579-84
pubmed: 21306485
J Int AIDS Soc. 2017 Jul 21;20(Suppl 4):22024
pubmed: 28770588
J Int AIDS Soc. 2016 Jul 20;19(5 Suppl 4):20846
pubmed: 27443273
Glob Public Health. 2011;6(1):83-97
pubmed: 20509066
J Acquir Immune Defic Syndr. 2017 Dec 15;76(5):453-460
pubmed: 28961678

Auteurs

Jake Pry (J)

Implementation Science Unit, Centre for Infectious Disease Research in Zambia (CIDRZ), Lusaka, Zambia.
Division of Infectious Diseases, School of Medicine, Washington University, St. Louis, MO, USA.

Jenala Chipungu (J)

Implementation Science Unit, Centre for Infectious Disease Research in Zambia (CIDRZ), Lusaka, Zambia.

Helene J Smith (HJ)

Implementation Science Unit, Centre for Infectious Disease Research in Zambia (CIDRZ), Lusaka, Zambia.

Carolyn Bolton Moore (C)

Implementation Science Unit, Centre for Infectious Disease Research in Zambia (CIDRZ), Lusaka, Zambia.
School of Medicine, University of Alabama, Birmingham, AL, USA.

Jacob Mutale (J)

Implementation Science Unit, Centre for Infectious Disease Research in Zambia (CIDRZ), Lusaka, Zambia.

Miquel Duran-Frigola (M)

Implementation Science Unit, Centre for Infectious Disease Research in Zambia (CIDRZ), Lusaka, Zambia.
Joint IRB-BSC-CRG Program in Computational Biology, Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Catalonia, Spain.

Theodora Savory (T)

Implementation Science Unit, Centre for Infectious Disease Research in Zambia (CIDRZ), Lusaka, Zambia.

Michael E Herce (ME)

Implementation Science Unit, Centre for Infectious Disease Research in Zambia (CIDRZ), Lusaka, Zambia.
Institute for Global Health & Infectious Diseases, School of Medicine, University of North Carolina, Chapel Hill, NC, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH